KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) EBIT Margin (2016 - 2026)

Abbott Laboratories' EBIT Margin history spans 18 years, with the latest figure at 12.05% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 430.0% to 12.05% in Q1 2026 year-over-year; TTM through Mar 2026 was 17.07%, a 23.0% increase, with the full-year FY2025 number at 18.17%, up 190.0% from a year prior.
  • EBIT Margin hit 12.05% in Q1 2026 for Abbott Laboratories, down from 19.64% in the prior quarter.
  • Over the last five years, EBIT Margin for ABT hit a ceiling of 24.48% in Q1 2022 and a floor of 12.05% in Q1 2026.
  • Historically, EBIT Margin has averaged 17.03% across 5 years, with a median of 17.0% in 2022.
  • Biggest five-year swings in EBIT Margin: skyrocketed 749bps in 2022 and later tumbled -900bps in 2023.
  • Tracing ABT's EBIT Margin over 5 years: stood at 12.92% in 2022, then surged by 35bps to 17.38% in 2023, then grew by 0bps to 17.41% in 2024, then increased by 13bps to 19.64% in 2025, then crashed by -39bps to 12.05% in 2026.
  • Business Quant data shows EBIT Margin for ABT at 12.05% in Q1 2026, 19.64% in Q4 2025, and 18.09% in Q3 2025.